- Point of View: Crystals against Cancer
- Disease Genomics
- Epigenetics as a Weapon to Treat Cancer
- Fully Automated Substance Discovery
- Big Data in Medicine
- Big Data: Biomedical Research
- Big Data: Bioinformatics
- Treating Diabetes in Asia
- Portrait Dra. Sommer
- Polycystic Ovary Syndrome
- More Articles
The Battle Against Sleeping Germs
It seemed that tuberculosis had been defeated, but that was wrong: a third of the world’s population is infected with these dangerous pathogens. Bayer’s scientists are currently carrying out clinical studies to find out whether the antibiotic moxifloxacin could help control this insidious disease. Combination therapy with three other drugs could significantly reduce treatment times.
Read on to find out how Bayer’s scientists are working with partners in a global network to design new treatment strategies to combat the dangerous tuberculosis bacteria:
This website is checked, operated and updated by BAYER at Leverkusen, Germany. It is intended for international use. However BAYER gives no guarantee that the details presented on this website are correct worldwide, and, in particular, that products and services will be available with the same appearance, in the same sizes or on the same conditions throughout the world. Should you call up this website or download contents, please note that it is your own responsibility to ensure that you act in compliance with local legislation applicable in that place.Products mentioned on this website may come in different packaging, in different package sizes, or with different lettering or markings, depending on the country.
In the USA the business of the Bayer Group is conducted by Bayer Corporation. Customers in the USA are requested to address to this entity.